REGENXBIO

Curran Simpson, SVP, Product Development and Chief Technology Officer
Rockville, MD
(NASDAQ: RGNX)
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
www.regenxbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions